379 related articles for article (PubMed ID: 33612558)
1. Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19.
Moriiwa Y; Morikawa G; Okazawa K; Yanagida A
Anal Sci; 2021 Sep; 37(9):1301-1304. PubMed ID: 33612558
[TBL] [Abstract][Full Text] [Related]
2. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma.
Megahed SM; Habib AA; Hammad SF; Kamal AH
Spectrochim Acta A Mol Biomol Spectrosc; 2021 Mar; 249():119241. PubMed ID: 33333412
[TBL] [Abstract][Full Text] [Related]
3. Favipiravir for COVID-19 in a Patient on Hemodialysis.
Hirai D; Yamashita D; Seta K
Am J Kidney Dis; 2021 Jan; 77(1):153-154. PubMed ID: 33011311
[No Abstract] [Full Text] [Related]
4. Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma.
Abdallah IA; Hammad SF; Bedair A; Mansour FR
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Jan; 1189():123087. PubMed ID: 34974319
[TBL] [Abstract][Full Text] [Related]
5. Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV.
Abdallah IA; Hammad SF; Bedair A; Elshafeey AH; Mansour FR
Bioanalysis; 2022 Feb; 14(4):205-216. PubMed ID: 35001648
[No Abstract] [Full Text] [Related]
6. Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma.
Hailat M; Al-Ani I; Hamad M; Zakareia Z; Abu Dayyih W
Molecules; 2021 Jun; 26(13):. PubMed ID: 34206357
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
[TBL] [Abstract][Full Text] [Related]
8. Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study.
Morikawa G; Kubota K; Kondo D; Takanashi Y; Minami S; Kinjo T; Moriiwa Y; Yanagida A; Okazawa K; Chiaki T
J Infect Chemother; 2022 Jan; 28(1):73-77. PubMed ID: 34711508
[TBL] [Abstract][Full Text] [Related]
9. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
10. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
11. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.
Ucan A; Cerci P; Efe S; Akgun H; Ozmen A; Yagmuroglu A; Bilgin M; Avci D
Virol J; 2021 May; 18(1):102. PubMed ID: 34034765
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of favipiravir in patients with COVID-19.
Irie K; Nakagawa A; Fujita H; Tamura R; Eto M; Ikesue H; Muroi N; Fukushima S; Tomii K; Hashida T
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1161-1170. PubMed ID: 34292670
[TBL] [Abstract][Full Text] [Related]
13. Core-shell nanocomposite of flower-like molybdenum disulfide nanospheres and molecularly imprinted polymers for electrochemical detection of anti COVID-19 drug favipiravir in biological samples.
Wang S; Wang C; Xin Y; Li Q; Liu W
Mikrochim Acta; 2022 Mar; 189(3):125. PubMed ID: 35229221
[TBL] [Abstract][Full Text] [Related]
14. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
15. A gadolinium-based magnetic ionic liquid for supramolecular dispersive liquid-liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma.
Abdallah IA; Hammad SF; Bedair A; Abdelaziz MA; Danielson ND; Elshafeey AH; Mansour FR
Biomed Chromatogr; 2022 Jun; 36(6):e5365. PubMed ID: 35274347
[TBL] [Abstract][Full Text] [Related]
16. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O; Lai WF
Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
[TBL] [Abstract][Full Text] [Related]
17. Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
Sirijatuphat R; Manosuthi W; Niyomnaitham S; Owen A; Copeland KK; Charoenpong L; Rattanasompattikul M; Mahasirimongkol S; Wichukchinda N; Chokephaibulkit K
Emerg Microbes Infect; 2022 Dec; 11(1):2197-2206. PubMed ID: 35997325
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
Irie K; Nakagawa A; Fujita H; Tamura R; Eto M; Ikesue H; Muroi N; Tomii K; Hashida T
Clin Transl Sci; 2020 Sep; 13(5):880-885. PubMed ID: 32475019
[TBL] [Abstract][Full Text] [Related]
20. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.
Murai Y; Kawasuji H; Takegoshi Y; Kaneda M; Kimoto K; Ueno A; Miyajima Y; Kawago K; Fukui Y; Ogami C; Sakamaki I; Tsuji Y; Morinaga Y; Yamamoto Y
Int J Infect Dis; 2021 May; 106():33-35. PubMed ID: 33746092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
